Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alli Approved OTC For Weight Loss With “Goal Oriented” Indication

This article was originally published in The Tan Sheet

Executive Summary

FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed

Related Content

GSK Alli Strategy Relies Even More On Users Spreading The Word
Switch Case Study: Alli Review Contrasts OTC, Rx Division Perspectives
Alli Users Show Self-Motivation Works Best, Side Effects Are “Positive”
GSK seeks to market orlistat in Europe
GSK Touts Alli As Tip Of OTC Strength, Reaffirms Consumer Commitment
Alli Lifestyle Marketing Plan Could Prompt Copies – Researchers
Alli Marketing Stresses Education, With Emphasis On Minority Groups – GSK
Behind-The-Counter Sale Works Without Regulation – Former FDA Counsel
Alli Marketing: While Vitamins Are Friendly, Some Supplements Are Foes
Alli Makes Passing Grade On Safety; Advisory Committee Debates Benefit





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts